-
Why Atlantis Protocol Became the Film Hollywood Could Not Make and Could Not Survive Without
By Kayla PavalDistinguished Magazine — Industry Analysis The year is 2032, and Hollywood is on life support. Not dying in the dramatic, cinematic way it knows how to sell, with an orchestral swell and a heroic last stand. Dying in the way things actually die: slowly, expensively, and with everyone involved pretending it is not…
-
Atlantis Protocol — The IMAX Event That Will Define a Generation
An IMAX Film Review by Kayla Paval I walked into the IMAX screening of Atlantis Protocol expecting a spectacle. Two hours and forty minutes later, I walked out a different person. Not because the film dazzled me, though it did, repeatedly, relentlessly, in ways that made my jaw physically ache from hanging open. Not because…
-
How Breakthrough Innovations Are Shaping the Future of Science
Every now and then, I find myself captivated by the sheer pace at which science and technology are evolving. It’s like we’re living in a time where tomorrow’s breakthroughs are materializing today, shaping our future in ways we once imagined only in science fiction. As someone who has always been fascinated by the boundary-pushing nature…
-
EU Moves Toward a Single Entry Point for Security Incident Reporting
On March 17, 2026, the European Parliament published a briefing signalling continued momentum toward the creation of an EU‑wide Single Entry Point (SEP) for security incident reporting. The initiative is part of the European Commission’s proposed Digital Omnibus legislative package and is intended to simplify how organizations report incidents – including personal data breaches –…
-
SEC and CFTC Draw Clear Lines for Crypto: What Is (and Isn’t) a Security
The Securities and Exchange Commission, with aligned guidance from the Commodity Futures Trading Commission, issued a comprehensive interpretation clarifying how federal securities laws apply to crypto assets and certain crypto transactions. The release introduces a functional taxonomy, explains when non‑security crypto assets can become subject to an investment contract under Howey, and addresses the securities…
-
Expel Annual Threat Report Shows Identity Compromise Continues to Be Threat Actors’ Favorite Tool
Cybersecurity firm Expel recently published its 2026 Threat Report, which analyzed over 1,000,000 alerts in its Security Operations Center throughout 2025. The results showed that threat actors continue to use compromised credentials to gain access to company systems….By: Robinson+Cole Data Privacy + Security Insider
-
No Good Deed Goes Unpunished: Victim Stryker Sued for Iranian-Backed Cyber Attack
As we reported last week, Stryker was attacked by Iranian-backed hackers in retaliation for Israeli and U.S. strikes against Iran. It was a significant cyberattack, known as a wiper attack. A wiper attack is designed not to extort money from a victim, but instead to send a message and destroy the victim’s data to cripple…
-
SEC Approves Nasdaq Rule Change Enabling Trading of Certain Tokenized Securities
The Securities and Exchange Commission (“SEC”) issued an order approving proposed amendments (the “Proposed Amendments”) by The Nasdaq Stock Market LLC (“Nasdaq” or “Exchange”) to the Exchange’s rules to enable trading of certain securities in tokenized form during the pendency of a tokenization pilot program (the “DTC Pilot”) operated by The Depository Trust Company (“DTC”)….By:…
-
TRUMP America AI Act Bill Sets Direction for Future US AI Regulation
On March 18, 2026, Senator Marsha Blackburn (R-TN) introduced the TRUMP AMERICA AI Act: formally, The Republic Unifying Meritocratic Performance Advancing Machine Intelligence by Eliminating Regulatory Interstate Chaos Across American Industry Act. This massive, 291 page bill sets out to establish the first comprehensive federal framework for artificial intelligence regulation in the United States….By: Fox…
-
GLP-1 Vision Loss Lawsuits: Ozempic, Wegovy, and NAION Optic Nerve Injury Claims
Patients who were prescribed Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), or other GLP-1 receptor agonist medications to treat type 2 diabetes or for weight loss may be at risk of vision loss or blindness from a condition known as non-arteritic anterior ischemic optic neuropathy (NAION)….By: Hissey, Mulderig & Friend, PLLC
